ADVANCED ACCELERATOR APPLICATIONS (UK & IRELAND) LIMITED

• ⚠

  Material uncertainty over going concern

  Following the sale of the business in June, the Directors have prepared the financial statements on a non-going concern basis. No specific accounting policies were affected by this decision. We draw attention to the disclosure made in note 2 of the financial statements which explains that the financial statement are now not prepared on going concern basis for the reason set out in that note. Our opinion is not modified in respect of this matter.

1. ADVANCED ACCELERATOR APPLICATIONS (UK & IRELAND) LIMITED 2020-01-02 → present
2. IMAGING EQUIPMENT LIMITED 2001-03-28 → 2020-01-02

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 102

Reporting scope

Standalone (parent only)

Auditor

KPMG LLP

Audit opinion

Unqualified (clean)

Going concern

Material uncertainty disclosed

“Following the sale of the business in June, the Directors have prepared the financial statements on a non-going concern basis. No specific accounting policies were affected by this decision. We draw attention to the disclosure made in note 2 of the financial statements which explains that the financial statement are now not prepared on going concern basis for the reason set out in that note. Our opinion is not modified in respect of this matter.”

Significant events

• “In 2022, Novartis reviewed all its operational activities including the sale of Radioligand Therapy Products (RLT) products ('transferred business'). As a result of the review, a decision was made by the Novartis Board to merge the RLT business with the rest of the Novartis business offering an efficient service to the customer. Consequently, on 1st of June 2024 the RLT business was transferred to Novartis Pharmaceuticals UK Limited except for the Generator business which was retained by the Company. The transfer was on an Asset purchase basis, valued at £7.8m. At time of transfer, it was agreed that the Company will settle all the balances in relation to transferred business on behalf of Novartis and subsequently settle with Novartis. At the end of the year, all such transactions had been settled by both the entities.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

5

last 12 months

Capital events

0

last 24 months

Officers appointed

2

last 12 months

Officers resigned

1

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  -41.6%

  £23,629,000 → £13,802,000

• Cash

  —

  Not reported

• Net assets

  +29%

  £6,475,000 → £8,350,000

• Employees

  -80.4%

  46 → 9

• Operating profit

  -24.4%

  £1,292,000 → £977,000

• Profit before tax

  +64.6%

  £1,516,000 → £2,495,000

• Wages

  -76.3%

  £4,157,000 → £987,000

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers